海岛地区非小细胞肺癌EGFR基因突变与临床病理特征的关系  

Relationship of epidermal growth factor receptor gene mutations in exons 19 and 21 and clinicopathologic features in patients with non-small cell lung cancer (NSCLC) in ZhouShan Archipelago

作　　者：竺王玉[1] 何剑营[1] 陈冬冬[1] 续力云[1] 刘晓光[1] 乐涵波[2] 张永奎[2] 

机构地区：[1]温州医学院附属舟山医院中科院免疫基因组学联合实验室,浙江舟山316004 [2]温州医学院附属舟山医院胸心外科,浙江舟山316004

出　　处：《中国卫生检验杂志》2013年第6期1359-1363,共5页Chinese Journal of Health Laboratory Technology

基　　金：浙江省科技厅项目(2011C37030)

摘　　要：目的:探讨舟山海岛地区非小细胞肺癌患者表皮生长因子受体(EGFR)19、21外显子的基因突变发生率及其与临床病理特征的相关性。方法:应用PCR扩增产物直接测序法检测129例非小细胞肺癌患者肿瘤组织EGFR基因19、21外显子突变,并分析其与临床病理资料的相关性。结果:129例肺癌患者中,共有35例发生EGFR基因突变(27.1%)。女性、非吸烟、腺癌及中高分化NSCLC患者EGFR基因突变率较高,是引起EGFR基因突变的危险因素(P<0.05)。Kaplan-Meier生存分析显示,NSCLC患者EGFR基因野生型及突变型生存率比较差异无统计学意义(P>0.05)。结论:舟山海岛地区肺癌患者EGFR突变发生率为27.1%,在女性、非吸烟、中高分化及肺腺癌患者中多见,但与总生存时间无明显相关。Objective： To investigate epidermal growth factor receptor （EGFR） gene mutations in exons 19 and 21 of patients with non - small cell lung cancer （NSCLC） and to analyze the relationship of EGFR mutations with clinicopathologic features in Zhoushan Archipelago. Methods： The EGFR gene exons 19 and 21 of tumor tissue were amplified by PCR, followed by direct sequencing in 129 surgically - removed specimens of NSCLC. The relationship of EGFR gene mutations in NSCLC with clinicopathologic features and prognosis were analyzed. Results： EGFR mutations were detected in 35 cases of 129 （27.1%） patients with NSCLC. Mutations were more frequently observed in women, non - smokers, adenocarcinoma patients and well - differentiated NSCLC patients, which were the risk factors for EGFR mutation （P 〈 0.05 ）. Kaplan - Meier survival analysis showed that the overall survival time of NSCLC patients with wild- type EGFR had no significant difference with patients with mutated EGFR（P 〉 0.05 ）. Conclusion： The rate of EGFR mutations occurred in Zhoushan Archipelago was 27. 1%, more frequently in females, non -smokers, adenocarcinoma patients and well -differentiated NSCLC patients, but it had no significant correlation with overall survival time.

关 键 词：非小细胞肺癌 表皮生长因子受体 基因突变 表皮生长因子受体酪氨酸激酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]